Search research articles
Contact Us
Filters
Showing results (81-90 of 101) with videos related to
Page
of 11
Sort By:
The Prostate
|
February 7, 2001
Synthetic inhibitor of matrix metalloproteinases (batimastat) reduces prostate cancer growth in an orthotopic rat model
M Lein, K Jung, D K Le, et al.
Der Urologe. Ausg. A
|
September 25, 2003
[An artificial neural network as a tool in risk evaluation of prostate cancer. Indication for biopsy with the PSA range of 2-20 microg/l]
C Stephan, B Vogel, H Cammann, et al.
International Journal of Cancer
|
March 10, 2000
Matrix-metalloproteinases and their inhibitors in plasma and tumor tissue of patients with renal cell carcinoma
M Lein, K Jung, C Laube, et al.
Der Anaesthesist
|
August 3, 2005
[Clinical pathway "laparoscopic prostatectomy". Analysis of anesthesiological procedures in a randomized study]
J-P Braun, M Walter, M Lein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 1, 1988
An update of two randomized trials in previously untreated multiple myeloma comparing melphalan and prednisone versus three- and five-drug combinations: an Argentine Group for the Treatment of Acute Leukemia Study
S Pavlovsky, C Corrado, M T Santarelli, et al.
Medicina
|
January 1, 1981
Evaluation of two combination chemotherapies in previously untreated non Hodgkin's lymphoma
N Somoza, S Pavlovsky, A Suárez, et al.
British Journal of Cancer
|
September 11, 2008
GOLPH2 protein expression as a novel tissue biomarker for prostate cancer: implications for tissue-based diagnostics
G Kristiansen, F R Fritzsche, K Wassermann, et al.
Physical Review Letters
|
January 21, 2022
Nonadiabatic Strong Field Ionization of Atomic Hydrogen
D Trabert, N Anders, S Brennecke, et al.
International Journal of Cancer
|
July 31, 2001
Molecular forms of prostate-specific antigen in serum with concentrations of total prostate-specific antigen <4 microg/L: are they useful tools for early detection and screening of prostate cancer?
K Jung, C Stephan, U Elgeti, et al.
Cancer Treatment Reports
|
January 1, 1980
Comparison of two combination chemotherapy regimens for multiple myeloma: methyl-CCNU, cyclophosphamide, and prednisone versus melphalan and prednisone
F Cavagnaro, J M Lein, S Pavlovsky, et al.
Page
of 11
Search research articles
Search
Showing results (81-90 of 101) with videos related to
Sort By:
Page
of 11
The Prostate
|
February 7, 2001
Synthetic inhibitor of matrix metalloproteinases (batimastat) reduces prostate cancer growth in an orthotopic rat model
M Lein, K Jung, D K Le, et al.
Der Urologe. Ausg. A
|
September 25, 2003
[An artificial neural network as a tool in risk evaluation of prostate cancer. Indication for biopsy with the PSA range of 2-20 microg/l]
C Stephan, B Vogel, H Cammann, et al.
International Journal of Cancer
|
March 10, 2000
Matrix-metalloproteinases and their inhibitors in plasma and tumor tissue of patients with renal cell carcinoma
M Lein, K Jung, C Laube, et al.
Der Anaesthesist
|
August 3, 2005
[Clinical pathway "laparoscopic prostatectomy". Analysis of anesthesiological procedures in a randomized study]
J-P Braun, M Walter, M Lein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 1, 1988
An update of two randomized trials in previously untreated multiple myeloma comparing melphalan and prednisone versus three- and five-drug combinations: an Argentine Group for the Treatment of Acute Leukemia Study
S Pavlovsky, C Corrado, M T Santarelli, et al.
Medicina
|
January 1, 1981
Evaluation of two combination chemotherapies in previously untreated non Hodgkin's lymphoma
N Somoza, S Pavlovsky, A Suárez, et al.
British Journal of Cancer
|
September 11, 2008
GOLPH2 protein expression as a novel tissue biomarker for prostate cancer: implications for tissue-based diagnostics
G Kristiansen, F R Fritzsche, K Wassermann, et al.
Physical Review Letters
|
January 21, 2022
Nonadiabatic Strong Field Ionization of Atomic Hydrogen
D Trabert, N Anders, S Brennecke, et al.
International Journal of Cancer
|
July 31, 2001
Molecular forms of prostate-specific antigen in serum with concentrations of total prostate-specific antigen <4 microg/L: are they useful tools for early detection and screening of prostate cancer?
K Jung, C Stephan, U Elgeti, et al.
Cancer Treatment Reports
|
January 1, 1980
Comparison of two combination chemotherapy regimens for multiple myeloma: methyl-CCNU, cyclophosphamide, and prednisone versus melphalan and prednisone
F Cavagnaro, J M Lein, S Pavlovsky, et al.
Page
of 11